Ascendis Pharma A/S (ASND) Metrics: History & Chart

Ascendis Pharma A/S(ASND)

Biotechnology · Hellerup, CR

$228.03+0.16 (+0.07%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

Hellerup, CR

1,189 employees

ascendispharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jan Moller Mikkelsen

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-0.88%
30D Total Return	-15.72%
YTD Total Return	+6.94%
1Y Total Return	+11.75%
3Y Total Return	+153.32%
5Y Total Return	+42.89%
10Y Total Return	+1026.91%
15Y Total Return	N/A
20Y Total Return	N/A

2026	+6.94%
2025	+54.89%
2024	+9.31%
2023	+3.13%
2022	-9.22%
2021	-19.34%
2020

CAGR TTM	+11.69%
CAGR 3Y	+36.31%
CAGR 5Y	+7.40%
CAGR 10Y	+27.41%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	17.33
PE Ratio Avg TTM	18.80
PE Ratio Avg 3Y	18.80
Current VS TTM Avg	-7.80%
Current VS 3Y Avg	-7.80%
Current VS 5Y Avg	-7.80%

All Metrics

ASND Valuation Metrics

ASND Stock Price Metrics

ASND Dividend Metrics

ASND Growth Rate Metrics

ASND Discounted Cash Flow Metrics

ASND Returns By Period

ASND Yearly Returns

ASND Average Annual Returns By Period (CAGR)

ASND Revenue Metrics

ASND PE Ratio Metrics

ASND PS Ratio Metrics

ASND PB Ratio Metrics

ASND Price to Free Cash Flow Ratio Metrics

ASND Debt to Equity Ratio Metrics

ASND PEG Ratio Metrics

ASND FCF Yield

ASND Earnings Yield

ASND EBITDA Yield

ASND OCF Yield

ASND EV/EBIT Ratio Metrics

ASND EV/EBITDA Ratio Metrics

ASND EV/Assets Ratio Metrics

ASND EV/Sales Ratio Metrics

ASND Current Ratio Metrics

ASND Quick Ratio Metrics

ASND ROIC Metrics

ASND Return on Assets Metrics

ASND Return on Equity Metrics

ASND Net Profit Margin Metrics

ASND Gross Profit Margin Metrics

ASND Tax Rate Metrics

PS Ratio	12.75
PS Ratio Avg TTM	16.30
PS Ratio Avg 3Y	22.06
Current VS TTM Avg	-21.79%
Current VS 3Y Avg	-42.19%
Current VS 5Y Avg	-80.67%

PB Ratio	9.50
PB Ratio Avg TTM	21.81
PB Ratio Avg 3Y	21.81
Current VS TTM Avg	-56.43%
Current VS 3Y Avg	-56.43%
Current VS 5Y Avg	-32.25%

PFCF Ratio	40.27
PFCF Ratio Avg TTM	297.43
PFCF Ratio Avg 3Y	297.43
Current VS TTM Avg	-86.46%
Current VS 3Y Avg	-86.46%
Current VS 5Y Avg	-86.46%

Debt/Equity Ratio	0.31
Debt/Equity Ratio Avg TTM	(2.42)
Debt/Equity Ratio Avg 3Y	(4.32)
Current VS TTM Avg	+112.94%
Current VS 3Y Avg	+107.25%
Current VS 5Y Avg	+118.36%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	2.48%
FCF Yield Avg TTM	0.34%
FCF Yield Avg 3Y	0.34%
Current VS TTM Avg	+630.95%
Current VS 3Y Avg	+630.95%
Current VS 5Y Avg	+630.95%

Earnings Yield	5.77%
Earnings Yield Avg TTM	5.34%
Earnings Yield Avg 3Y	5.34%
Current VS TTM Avg	+8.07%
Current VS 3Y Avg	+8.07%
Current VS 5Y Avg	+8.07%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	120.36
Ev/Ebit Ratio Avg TTM	130.84
Ev/Ebit Ratio Avg 3Y	130.84
Current VS TTM Avg	-8.01%
Current VS 3Y Avg	-8.01%
Current VS 5Y Avg	-8.01%

Ev/Ebitda Ratio	103.45
Ev/Ebitda Ratio Avg TTM	953.43
Ev/Ebitda Ratio Avg 3Y	953.43
Current VS TTM Avg	-89.15%
Current VS 3Y Avg	-89.15%
Current VS 5Y Avg	-89.15%

Ev/Assets Ratio	5.81
Ev/Assets Ratio Avg TTM	8.55
Ev/Assets Ratio Avg 3Y	8.44
Current VS TTM Avg	-32.06%
Current VS 3Y Avg	-31.13%
Current VS 5Y Avg	-16.98%

Ev/Sales Ratio	12.41
Ev/Sales Ratio Avg TTM	16.58
Ev/Sales Ratio Avg 3Y	22.79
Current VS TTM Avg	-25.13%
Current VS 3Y Avg	-45.56%
Current VS 5Y Avg	-79.66%

Current Ratio	2.99
Current Ratio Avg TTM	1.41
Current Ratio Avg 3Y	1.00
Current VS TTM Avg	+111.37%
Current VS 3Y Avg	+199.69%
Current VS 5Y Avg	-24.30%

Quick Ratio	2.32
Quick Ratio Avg TTM	1.04
Quick Ratio Avg 3Y	0.72
Current VS TTM Avg	+122.69%
Current VS 3Y Avg	+221.61%
Current VS 5Y Avg	-32.42%

ROIC	5.85%
ROIC Avg 3Y	(49.34%)
ROIC Avg 5Y	(49.50%)
Current VS 3Y Avg	+111.86%
Current VS 5Y Avg	+111.82%
Current VS 10Y Avg	+111.92%

ROA	33.29%
ROA Avg TTM	5.94%
ROA Avg 3Y	(8.17%)
Current VS TTM Avg	+460.45%
Current VS 3Y Avg	+507.47%
Current VS 5Y Avg	+418.67%

ROE	52.97%
ROE Avg TTM	78.10%
ROE Avg 3Y	(249.62%)
Current VS TTM Avg	-32.18%
Current VS 3Y Avg	+121.22%
Current VS 5Y Avg	+134.27%

Net Profit Margin	71.08%
Net Profit Margin Avg TTM	49.90%
Net Profit Margin Avg 3Y	(115.88%)
Current VS TTM Avg	+42.44%
Current VS 3Y Avg	+161.34%
Current VS 5Y Avg	+115.35%

Gross Profit Margin	90.18%
Gross Pft Margin Avg TTM	88.11%
Gross Pft Margin Avg 3Y	84.56%
Current VS TTM Avg	+2.35%
Current VS 3Y Avg	+6.65%
Current VS 5Y Avg	+4.83%

Tax Rate	10.05%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A